Caen Cedex 5

• Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended
  2024-512826-26-00 4 2022-03-07 Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ b
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokin … Ended
  2024-518362-27-00 1 2021-05-18 Patients with recurrent and/or metastatic solid cancer.
• A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1 P … Ended
  2023-509449-10-00 4 2021-03-16 Squamous cell carcinoma of the head and neck (SCCHN)
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga … Ended
  2023-504834-23-00 11 2021-02-24 Advanced/Metastatic Gastroesophageal Adenocarcinoma
• Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended
  2023-504944-32-00 4 2021-02-17 Non-clear Cell Renal Cell Carcinoma
• Efficacy of immunotherapy in combination with a drug in patients with advanced mucosal cancer of different locations that has progress. Ended
  2023-510320-71-00 4 2020-10-27 Squamous cell carcinoma of vulva/vagina
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer Ended
  2023-506248-18-00 7 2020-01-07 MET-altered non-small cell lung cancer (NSCLC)
• A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended
  2024-516201-23-00 4 2019-08-26 Lung Cancer, NSCLC
• Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Ended
  2024-513977-31-00 4 2019-07-17 Untreated squamous cell carcinoma of the head and neck
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma … Ended
  2024-511316-25-00 3 2019-06-04 Urothelial carcinoma (UC)
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi … Ended
  2024-514179-17-00 5 2018-10-02 Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
• Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo … Ended
  2024-514586-20-01 5 2018-05-02 Non small cell lung cancer
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab ( … Ended
  2024-515000-39-00 9 2017-01-17 Recurrent glioblastoma.
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative settin … Ended
  2024-514078-29-00 4 gastric and gastro-oesophageal junction adenocarcinomas
• Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc … Ended
  2024-515533-15-00 4 Locally advanced cervical cancer
• Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre … Ended
  2024-516724-33-00 9 Advanced/metastatic gynecological cancer overexpressing FGFR2b

Showing 265–287 of 287 trials